Anna Kozłowska

ORCID: 0000-0003-2465-217X
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Immune Cell Function and Interaction
  • Immunotherapy and Immune Responses
  • CAR-T cell therapy research
  • T-cell and B-cell Immunology
  • Cancer Immunotherapy and Biomarkers
  • Immune Response and Inflammation
  • Cancer Research and Treatments
  • Epigenetics and DNA Methylation
  • Immune cells in cancer
  • Cytokine Signaling Pathways and Interactions
  • Bone health and treatments
  • RNA Interference and Gene Delivery
  • Mesenchymal stem cell research
  • Oral and gingival health research
  • Virus-based gene therapy research
  • Hematopoietic Stem Cell Transplantation
  • Bone and Joint Diseases
  • Histone Deacetylase Inhibitors Research
  • Immunodeficiency and Autoimmune Disorders
  • Fibroblast Growth Factor Research
  • Invertebrate Immune Response Mechanisms
  • Protein Degradation and Inhibitors
  • Reproductive System and Pregnancy
  • Chemokine receptors and signaling
  • Urticaria and Related Conditions

AstraZeneca (Sweden)
2023-2025

AstraZeneca (United Kingdom)
2024

Poseida Therapeutics (United States)
2020-2021

Poznan University of Medical Sciences
2009-2020

University of California, Los Angeles
2015-2019

City of Hope
2013-2018

UCLA Jonsson Comprehensive Cancer Center
2017

Ronald Reagan UCLA Medical Center
2015

Beckman Research Institute
2013

Institut de Recherche Vaccinale
2013

Impressive clinical efficacy of chimeric antigen receptor (CAR)-engineered T cell therapy for hematological malignancies have prompted significant efforts in achieving similar responses solid tumors. The lack truly restricted and uniform expression tumor-associated antigens, as well limited persistence and/or tumor trafficking pose major challenges successful translation CAR Recent studies demonstrated that aberrantly glycosylated surface proteins on cells are amenable targets....

10.3389/fimmu.2018.02268 article EN cc-by Frontiers in Immunology 2018-11-19

Abstract Cancer radiotherapy may be immunogenic, but it is unclear why its immunogenic effects are rarely sufficient to prevent tumor recurrence. Here, we report a novel Toll-like receptor 9 (TLR9)–dependent mechanism that initiates regrowth after local radiotherapy. Systemic inhibition of TLR9, not TLR4, delayed recurrence in mouse models B16 melanoma, MB49 bladder cancer, and CT26 colon cancer localized high-dose irradiation. Soluble factors the microenvironment regressing tumors triggered...

10.1158/0008-5472.can-13-1314 article EN Cancer Research 2013-10-24

// Han-Ching Tseng 1, * , Keiichi Kanayama 2, 3, Kawaljit Kaur So-Hyun Park 1 Sil 2 Anna Kozlowska 4 Shuting Sun 5 Charles E. McKenna Ichiro Nishimura Anahid Jewett Division of Oral Biology and Medicine, The Jane Jerry Weintraub Center for Reconstructive Biotechnology, UCLA School Dentistry, Los Angeles, CA, USA Advanced Prosthodontics, 3 Department Periodontology, Asahi University Gifu, Japan Tumor Immunology, Poznan Medical Sciences Poznan, Poland Chemistry, Southern California, These...

10.18632/oncotarget.4755 article EN Oncotarget 2015-07-28

Natural Killer (NK) cells target oral, pancreatic, lung, breast, glioblastoma and melanoma stem-like/poorly differentiated tumors. Differentiation of the abovementioned tumors with supernatants from split-anergized NK decreases their susceptibility to cells, but increases sensitivity cisplatin (CDDP)-mediated cell death. Breast tumor CD44 knockdown display enhanced cell-mediated lysis, potentially due decreased differentiation. We also demonstrate that sulindac, a non-steroidal...

10.7150/jca.15989 article EN cc-by-nc Journal of Cancer 2017-01-01

Natural killer (NK) cells are known to target cancer stem and undifferentiated tumors. In this paper, we provide a novel strategy for expanding large numbers of super-charged NK with significant potential lyse differentiate demonstrate the differences in dynamics cell expansion between healthy donors patients. Decline cytotoxicity lower interferon (IFN)-γ secretion by osteoclast (OC)-expanded from patients correlates faster residual contaminating T within purified cells, whereas donors' OCs...

10.3389/fimmu.2017.00297 article EN cc-by Frontiers in Immunology 2017-04-05

Our previous reports demonstrated that the magnitude of NK cell mediated cytotoxicity correlated directly with stage and levels differentiation tumor cells. In addition, we have shown previously activated cells induce growth inhibition cancer through induction resulting in resistance to secreted cytokines, as well direct NK-tumor contact. this report show comparison IL-2+anti-CD16mAb treated cells, activation by probiotic bacteria sAJ2 combination IL-2 anti-CD16mAb substantially decreases...

10.3389/fimmu.2015.00576 article EN cc-by Frontiers in Immunology 2015-12-02

Therapeutic role of NK cells in solid tumors was challenged previously even though their hematological malignancies has clearly been established. Furthermore, functions and numbers are greatly suppressed oral cancer patients necessitating effective future immunotherapeutic strategies to aid the control disease. The humanized-BLT (hu-BLT) mice were used implant stem-like/undifferentiated study super-charged with without feeding AJ2 probiotic bacteria. Implanted CSC/undifferentiated resected...

10.1080/2162402x.2018.1426518 article EN OncoImmunology 2018-01-15

Background and Aims: We have previously demonstrated that the stage of differentiation tumors has profound effect on function NK cells, stem-like/poorly differentiated were preferentially targeted by cells. Therefore, in this study we determined role super-charged cells immune mobilization, lysis, stem-like/undifferentiated implanted pancreas humanized-BLT (hu-BLT) mice fed with or without AJ2 probiotics. The phenotype, growth rate metastatic potential pancreatic (NK-differentiated) patient...

10.3390/cancers12010063 article EN Cancers 2019-12-24

Abstract Background Regulatory T cells (Treg) are a subset of CD4+ that play crucial role in maintaining immune tolerance and preventing autoimmunity. In the context Inflammatory Bowel Disease (IBD), dysregulation Treg function has been implicated pathogenesis disease. Studies have shown polyclonal potential to suppress inflammatory responses ameliorate colitis preclinical models. This led growing interest harnessing therapeutic as treatment for IBD. To support this new research effectively...

10.1093/ecco-jcc/jjae190.0255 article EN Journal of Crohn s and Colitis 2025-01-01

The list of genes, which augment NK cell function when knocked out in neighboring cells is increasing, and may point to the fundamental targeting with diminished capability differentiate optimally since are able target less differentiated cells, aid their differentiation. In this paper, we aimed at understanding effect monocytes from targeted knockout COX-2 myeloid (Cox-2(flox/flox);LysM(Cre/) (+)) control littermates (Cox-2(flox/flox);LysM (+) (/) on ex vivo cells. Furthermore, compared...

10.3389/fimmu.2015.00259 article EN cc-by Frontiers in Immunology 2015-06-09

Abstract Mesenchymal stromal cell (MSC) apoptosis is required for in vivo immunosuppression. However, the induction of heavily dependent on recipient’s immune system. In graft-versus-host disease (GvHD), patients who fail to respond MSCs are fact those whose cells unable induce MSC ex vivo. The information critical explain why responses clinical trials vary even though same sources products infused. More importantly, it highlights need an alternative treatment nonresponders. By using a mouse...

10.1093/stcltm/szae061 article EN cc-by-nc Stem Cells Translational Medicine 2024-08-07

ABSTRACT Allogeneic whole cell gene modified therapeutic melanoma vaccine (AGI-101H) comprising of two lines transduced with cDNA encoding fusion protein composed IL-6 linked the soluble receptor (sIL-6R), referred to as H6 was developed. served a molecular adjuvant, however, it has altered cells phenotype towards stem (MSC)-like high activity aldehyde dehydrogenase isoenzyme (ALDH1A1). AGI-101H applied in advanced patients non-resected and resected disease. In adjuvant setting, combined...

10.1080/2162402x.2018.1509821 article EN OncoImmunology 2018-08-24

Therapeutic cancer vaccines have elicited renewed interest due to the development of immune checkpoint inhibitors. The role these is induce specific effector cells for killing cells. Cancer stem (CSCs) are responsible tumor growth and progression. Accordingly, they targets various therapies, including immunotherapy. Here, we demonstrate effectiveness melanoma composed genetically modified admixed with stem-like (MSC) or induced pluripotent (iPSCs). Two were constructed. first vaccine...

10.3390/vaccines8020147 article EN cc-by Vaccines 2020-03-26

Objective. CD4+ T cells from patients with systemic lupus erythematosus (SLE) display defective function that contributes to abnormal activation of B and autoantibody production. Methods. We compared the transcript protein levels Fyn CD70 in SLE (n = 41) healthy individuals 34). The were isolated by positive biomagnetic separation technique. quantitative analysis messenger RNA was performed reverse transcription real-time PCR. contents determined Western blotting analysis. Results. observed...

10.3899/jrheum.090424 article EN The Journal of Rheumatology 2009-12-01
Coming Soon ...